Dermatology specialist Galderma (SWX:GALD) announced on Friday that its regenerative biostimulator Sculptra has received EU Medical Device Regulation (MDR) certification, extending its use beyond facial applications to the gluteal area, posterior thighs, décolletage, and upper arms.
This expanded indication positions Sculptra to address broader aesthetic goals, including improvements in skin quality, firmness, lift, projection, and contour.
Clinical studies show progressive enhancements across these body areas, including improved skin texture and cellulite appearance.
Galderma said that the certification affirms Sculptra's safety, efficacy, and quality as a regenerative biostimulator. The company noted rising patient demand for comprehensive aesthetic solutions, with nine out of ten women reporting concerns beyond the face.
Growing interest in non-surgical body treatments, particularly for gluteal shaping, underscores the relevance of Sculptra's collagen and elastin–boosting effects.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis